Drugs
All drugs and treatments tracked across rare diseases on Kipine, with evidence-linked profiles and cross-disease comparisons.
20 drugs tracked
Drug2 diseases
Anakinra
IL-1 receptor antagonist
Schnitzler Syndrome · ~94% · 1st lineCryopyrin-Associated Periodic Syndromes · Sustained efficacy up to 5 years · 1st line
Drug2 diseases
Canakinumab
Anti–IL-1β monoclonal antibody
Schnitzler Syndrome · High (RCT confirmed) · 2nd lineCryopyrin-Associated Periodic Syndromes · 78-97% complete response · 1st line
Drug2 diseases
Corticosteroids
Broad anti-inflammatory
Schnitzler Syndrome · Temporary, partial · Not recommended lineCryopyrin-Associated Periodic Syndromes · Partial, temporary · Supportive line
Drug2 diseases
Rilonacept
IL-1 decoy receptor
Schnitzler Syndrome · Limited data · Alternative lineCryopyrin-Associated Periodic Syndromes · Significant improvement vs placebo · 2nd line
Drug
Aspirin desensitisation
COX-1 tolerance induction
Chronic Rhinosinusitis with Nasal Polyps · Effective in AERD · AERD-specific line
Drug
Benralizumab
Anti–IL-5Rα monoclonal antibody (ADCC-mediated eosinophil depletion)
Chronic Rhinosinusitis with Nasal Polyps · Near-complete eosinophil depletion · 1st-line biologic line
Drug
Bortezomib
Proteasome inhibitor
Schnitzler Syndrome · Single case report · Investigational line
Drug
Dapansutrile
Oral NLRP3 inflammasome inhibitor
Cryopyrin-Associated Periodic Syndromes · Phase 2a (no CAPS efficacy data yet) · Experimental line
Drug
Dupilumab
Anti–IL-4Rα monoclonal antibody (blocks IL-4 and IL-13)
Chronic Rhinosinusitis with Nasal Polyps · ~75% polyp reduction · 1st-line biologic line
Drug
Functional endoscopic sinus surgery (FESS)
Surgical polyp removal and sinus drainage
Chronic Rhinosinusitis with Nasal Polyps · Immediate symptom relief · 1st (surgical) line
Drug
Ibrutinib
BTK inhibitor
Schnitzler Syndrome · Complete in case reports · Alternative line
Drug
Intranasal corticosteroids
Topical anti-inflammatory
Chronic Rhinosinusitis with Nasal Polyps · Modest polyp reduction · 1st line
Drug
Leukotriene receptor antagonists
CysLT1 receptor blockade (montelukast)
Chronic Rhinosinusitis with Nasal Polyps · Modest in AERD subtype · Adjunctive line
Drug
Mepolizumab
Anti–IL-5 monoclonal antibody
Chronic Rhinosinusitis with Nasal Polyps · Significant NPS reduction · 1st-line biologic line
Drug
NSAIDs
COX inhibition
Cryopyrin-Associated Periodic Syndromes · Symptomatic only · Supportive line
Drug
Omalizumab
Anti-IgE monoclonal antibody
Chronic Rhinosinusitis with Nasal Polyps · Significant NPS reduction · 1st-line biologic line
Drug
Oral corticosteroids (short course)
Systemic anti-inflammatory
Chronic Rhinosinusitis with Nasal Polyps · Rapid polyp shrinkage · Rescue line
Drug
Rituximab
Anti-CD20 (B-cell depletion)
Schnitzler Syndrome · Ineffective on inflammation · Not recommended line
Drug
Saline nasal irrigation
Mechanical clearance / mucosal hydration
Chronic Rhinosinusitis with Nasal Polyps · Symptom improvement · Adjunctive line
Drug
Tocilizumab
Anti–IL-6 receptor
Schnitzler Syndrome · Temporary · Alternative line